Foreign institutional investors (FIIs) have raised their stake in Lupin by 206 basis points to 36.75 percent at the end of June 2015 from 34.69 percent as on March 31, 2015. On the other hand, domestic institutional investors (DIIs) have decreased their stake in the company by 185 basis points to 6.82 percent at the end of June 2015 from 8.67 percent as on March 31, 2015.
Non Institutions were holding 9.84 percent stake at the end of June 2015, down 17 basis points from 10.01 percent as on March 31, 2015, while corporate bodies were holding 1.1 percent stake at the end of June 2015, down 4 basis points from 1.14 percent as on March 31, 2015.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products.
